318 related articles for article (PubMed ID: 30019530)
21. Value of the first post-transplant biopsy for predicting long-term cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patients.
Labarrere CA; Woods JR; Hardin JW; Campana GL; Ortiz MA; Jaeger BR; Baldridge LA; Pitts DE; Kirlin PC
PLoS One; 2012; 7(4):e36100. PubMed ID: 22558345
[TBL] [Abstract][Full Text] [Related]
22. Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography.
Zanchin C; Yamaji K; Rogge C; Lesche D; Zanchin T; Ueki Y; Windecker S; Mohacsi P; Räber L; Sigurdardottir V
PLoS One; 2018; 13(8):e0202950. PubMed ID: 30148864
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
Choi HI; Kang DY; Kim MS; Lee SE; Ahn JM; Lee JY; Kim YH; Park DW; Jung SH; Kim JJ
Atherosclerosis; 2022 Sep; 357():1-8. PubMed ID: 35981436
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
Arora S; Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Sigurdardottir V; Dellgren G; Erikstad I; Solberg OG; Ueland T; Aukrust P; Gullestad L;
Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
[TBL] [Abstract][Full Text] [Related]
25. Early aspirin use and the development of cardiac allograft vasculopathy.
Kim M; Bergmark BA; Zelniker TA; Mehra MR; Stewart GC; Page DS; Woodcome EL; Smallwood JA; Gabardi S; Givertz MM
J Heart Lung Transplant; 2017 Dec; 36(12):1344-1349. PubMed ID: 28781013
[TBL] [Abstract][Full Text] [Related]
26. Cardiac PET Myocardial Blood Flow Quantification Assessment of Early Cardiac Allograft Vasculopathy.
Chih S; Tavoosi A; Nair V; Chong AY; Džavík V; Aleksova N; So DY; deKemp RA; Amara I; Wells GA; Bernick J; Overgaard CB; Celiker-Guler E; Mielniczuk LM; Stadnick E; McGuinty C; Ross HJ; Beanlands RSB
JACC Cardiovasc Imaging; 2024 Jun; 17(6):642-655. PubMed ID: 37999656
[TBL] [Abstract][Full Text] [Related]
27. Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients.
Asleh R; Alnsasra H; Lerman A; Briasoulis A; Pereira NL; Edwards BS; Toya T; Stulak JM; Clavell AL; Daly RC; Kushwaha SS
Am J Transplant; 2021 Feb; 21(2):626-635. PubMed ID: 32558174
[TBL] [Abstract][Full Text] [Related]
28. Reduced progression of cardiac allograft vasculopathy with routine use of induction therapy with basiliximab.
Wang R; Moura LA; Lopes SV; Costa FD; Souza Filho NF; Fernandes TL; Salvatti NB; Faria-Neto JR
Arq Bras Cardiol; 2015 Aug; 105(2):176-83. PubMed ID: 26107815
[TBL] [Abstract][Full Text] [Related]
29. PET assessment of myocardial perfusion reserve inversely correlates with intravascular ultrasound findings in angiographically normal cardiac transplant recipients.
Wu YW; Chen YH; Wang SS; Jui HY; Yen RF; Tzen KY; Chen MF; Lee CM
J Nucl Med; 2010 Jun; 51(6):906-12. PubMed ID: 20484427
[TBL] [Abstract][Full Text] [Related]
30. Peripheral microvascular dysfunction is associated with plaque progression and adverse long-term outcomes in heart transplant patients.
Ozcan I; Toya T; Corban MT; Ahmad A; Lerman LO; Kushwaha SS; Lerman A
ESC Heart Fail; 2021 Dec; 8(6):5266-5274. PubMed ID: 34510802
[TBL] [Abstract][Full Text] [Related]
31. Early optical coherence tomography evaluation of donor-transmitted atherosclerosis and cardiac allograft vasculopathy: insights from a prospective, single-center study.
Takahashi T; Kobayashi Y; Saeed O; Vukelic S; Jorde UP; Shin JJ; Patel SR
J Heart Lung Transplant; 2023 Dec; 42(12):1678-1687. PubMed ID: 37454771
[TBL] [Abstract][Full Text] [Related]
32. Donor-Transmitted Atherosclerosis Associated With Worsening Cardiac Allograft Vasculopathy After Heart Transplantation: Serial Volumetric Intravascular Ultrasound Analysis.
Watanabe T; Seguchi O; Yanase M; Fujita T; Murata Y; Sato T; Sunami H; Nakajima S; Kataoka Y; Nishimura K; Hisamatsu E; Kuroda K; Okada N; Hori Y; Wada K; Hata H; Ishibashi-Ueda H; Miyamoto Y; Fukushima N; Kobayashi J; Nakatani T
Transplantation; 2017 Jun; 101(6):1310-1319. PubMed ID: 27472091
[TBL] [Abstract][Full Text] [Related]
33. Cardiac allograft vasculopathy and graft failure in pediatric heart transplant recipients after rejection with severe hemodynamic compromise.
Kleinmahon JA; Gralla J; Kirk R; Auerbach SR; Henderson HT; Wallis GA; Ramakrishnan K; Singh RK; Caldwell RL; Savage AJ; Everitt MD
J Heart Lung Transplant; 2019 Mar; 38(3):277-284. PubMed ID: 30638837
[TBL] [Abstract][Full Text] [Related]
34. Genetic and Functional Profiling of CD16-Dependent Natural Killer Activation Identifies Patients at Higher Risk of Cardiac Allograft Vasculopathy.
Paul P; Picard C; Sampol E; Lyonnet L; Di Cristofaro J; Paul-Delvaux L; Lano G; Nicolino-Brunet C; Ravis E; Collart F; Dignat-George F; Dussol B; Sabatier F; Mouly-Bandini A
Circulation; 2018 Mar; 137(10):1049-1059. PubMed ID: 29097449
[TBL] [Abstract][Full Text] [Related]
35. Circulating progenitor cells are associated with plaque progression and long-term outcomes in heart transplant patients.
Ozcan I; Toya T; Corban MT; Ahmad A; Loeffler D; Morse D; Lerman LO; Kushwaha SS; Lerman A
Cardiovasc Res; 2022 Jun; 118(7):1703-1712. PubMed ID: 34132771
[TBL] [Abstract][Full Text] [Related]
36. Optical coherence tomography for characterization of cardiac allograft vasculopathy in late survivors of pediatric heart transplantation.
Tomai F; De Luca L; Petrolini A; Di Vito L; Ghini AS; Corvo P; De Persio G; Parisi F; Pongiglione G; Giulia Gagliardi M; Prati F
J Heart Lung Transplant; 2016 Jan; 35(1):74-79. PubMed ID: 26452998
[TBL] [Abstract][Full Text] [Related]
37. Intravascular ultrasound for assessment of coronary allograft vasculopathy.
König A; Theisen K; Klauss V
Z Kardiol; 2000; 89 Suppl 9():IX/45-9. PubMed ID: 11151792
[TBL] [Abstract][Full Text] [Related]
38. Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation.
Sánchez Lázaro IJ; Almenar Bonet L; Moro López J; Sánchez Lacuesta E; Martínez-Dolz L; Agüero Ramón-Llín J; Andrés Lalaguna L; Cano Pérez O; Ortiz Martínez V; Buendía Fuentes F; Salvador Sanz A
Transplant Proc; 2008 Nov; 40(9):3056-7. PubMed ID: 19010192
[TBL] [Abstract][Full Text] [Related]
39. Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation.
Tremblay-Gravel M; Racine N; de Denus S; Ducharme A; Pelletier GB; Giraldeau G; Liszkowski M; Parent MC; Carrier M; Fortier A; White M
JACC Heart Fail; 2017 Dec; 5(12):891-901. PubMed ID: 29191295
[TBL] [Abstract][Full Text] [Related]
40. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy.
Martínez-Dolz L; Almenar L; Reganon E; Vila V; Chamorro C; Andrés L; Martínez-Sales V; Moro J; Agüero J; Sánchez-Lázaro I; Salvador A
J Heart Lung Transplant; 2008 Jul; 27(7):760-6. PubMed ID: 18582806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
